Last updated: May 4, 2026
What is Vasotec and what is its current clinical footprint?
Vasotec is the brand name for enalapril, an oral ACE inhibitor indicated for hypertension and congestive heart failure (CHF). The product line includes Vasotec tablets and Vasotec Injection for selected clinical settings.
Therapeutic maturity: Vasotec’s active ingredient (enalapril) is well beyond initial launch and is now a mature, off-patent standard-of-care ACE inhibitor in most markets. As a result, the public clinical-trials pipeline is dominated by:
- observational studies, registries, and comparative effectiveness research using enalapril as a comparator
- new labeling/biomarker substudies rather than first-in-class development
- formulation, dosing, and comparative pharmacology studies rather than pivotal new-efficacy programs
Implication for “clinical trials update”: A practical clinical update for Vasotec is typically limited to label-relevant studies and postmarketing evidence rather than new Phase 3 programs.
Which active or recruiting clinical trials exist for enalapril/Vasotec?
No complete, up-to-date trial-by-trial listing can be produced here because the request requires current registry data (e.g., ClinicalTrials.gov status, sponsor, phase, endpoints, and timelines) and the necessary live data source is not provided in the prompt.
What does the market look like for enalapril (Vasotec) by geography and channel?
Because Vasotec is off-patent in most major markets, the economic reality is driven by:
- generic enalapril penetration
- price erosion from multi-source supply
- payer reimbursement dynamics
- distribution channel breadth in ambulatory care
Competitive structure
- Primary competitors: other generic ACE inhibitors (e.g., lisinopril, captopril, ramipril) and branded cardiovascular agents where relevant
- Direct substitutes: generic enalapril products and fixed-dose combinations where used by patients
Key demand drivers
- prevalence of hypertension and CHF
- chronic adherence patterns (ACE inhibitors remain long-term therapy)
- guideline placement of ACE inhibitors in CHF and hypertension management
Channel reality
- Low-cost chronic cardiometabolic therapy is predominantly primary care and cardiology driven
- Hospital use of ACE inhibitors exists but is also heavily genericized, compressing pricing
How should an investor model Vasotec/enalapril sales when it is off-patent?
For off-patent ACE inhibitors, forecasting is usually less about blockbuster-style growth and more about share, price erosion, and formulary persistence.
A workable projection framework uses these components:
- Underlying treated population (hypertension and CHF cohorts)
- Utilization rate (ACE inhibitor share within those cohorts)
- Price erosion (generic competition and periodic downward pricing)
- Share retention (brand vs generic mix; or, if you are modeling a branded manufacturer, the share of branded remaining demand)
- Switching dynamics (patients and prescribers can shift across ACE inhibitors and to ARBs or ARNI depending on tolerability)
What is the projection for Vasotec’s market performance?
A quantified market projection requires:
- an explicit market definition (e.g., US prescriptions, EU defined daily doses, global spend)
- baseline sales, units, and time series
- current branded vs generic split
- country coverage and forecast horizon
Those inputs are not present in the prompt, so a complete numeric forecast cannot be generated without fabricating assumptions.
How do clinical evidence and guideline positioning affect enalapril demand?
Even when development is not active, clinical positioning continues to influence steady demand:
- ACE inhibitors remain foundational in CHF management and common in hypertension therapy
- evidence base supports outcome benefit class-wide, not unique to enalapril alone
- safety and tolerability factors (renal function monitoring, hyperkalemia risk, cough, angioedema vigilance) drive prescribing but do not eliminate use
What should be monitored next for Vasotec as a business?
With an off-patent ACE inhibitor, risk and opportunity monitoring is typically focused on:
- generic supply changes and price competition in each major market
- formulary status shifts for competitor ACE inhibitors and ARBs/ARNI classes
- regulatory and manufacturing updates that affect availability and tender outcomes
- utilization shifts for CHF phenotypes and guideline updates that affect ACE inhibitor vs ARB vs ARNI selection
Key Takeaways
- Vasotec (enalapril) is a mature, off-patent ACE inhibitor where public “clinical trial updates” are usually limited to postmarketing, observational, and comparator studies rather than new pivotal efficacy programs.
- Demand is primarily driven by chronic management of hypertension and CHF, while revenue is shaped by generic penetration and price erosion rather than innovation-led growth.
- A quantified clinical-trials inventory and a numerical market projection cannot be completed from the provided prompt because it lacks live registry data and baseline market figures.
FAQs
1) Is Vasotec still undergoing Phase 3 trials?
Not typically. For an off-patent ACE inhibitor like enalapril, public development is usually smaller studies rather than new Phase 3 pivotal programs.
2) What is Vasotec used for today?
It is used for hypertension and congestive heart failure, consistent with ACE inhibitor indications.
3) What most affects enalapril sales?
Generic pricing and formulary positioning, plus treated-population size and utilization in hypertension and CHF.
4) How does competition impact Vasotec?
Multi-source generics compress price; competitors include other ACE inhibitors and therapy alternatives within cardiovascular care.
5) What is the best way to forecast off-patent enalapril?
Model treated population and utilization share, then apply price erosion and expected share retention by channel and country.
References
[1] DailyMed. “VASOTEC (enalapril maleate) tablet and injection label.” U.S. National Library of Medicine.
[2] ClinicalTrials.gov. “Enalapril” and “enalapril maleate” search results. U.S. National Library of Medicine.
[3] FDA. “Drug Approval Reports” and related enalapril approval documentation. U.S. Food and Drug Administration.
